Innovations in clinical research design and conduct in psychiatry: Shifting to pragmatic approaches

Psychiatry Investigation

Volumn 6, Issue 1, 2009, Pages 1-6

  Marks, David M ^a   Thanaseelan, J ^a   Pae, Chi Un ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The Catholic University of Korea   (South Korea)

Author keywords

Innovation; Psychiatric research; Strategies

Indexed keywords

ADAPTIVE DESIGN; ANALYTICAL ERROR; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL STUDY; EQUIPOISE STRATIFIED DESIGN; INFORMED CONSENT; INTERMETHOD COMPARISON; METHODOLOGY; PLACEBO EFFECT; PSYCHIATRIC TREATMENT; RANDOMIZATION; RESEARCH ETHICS; REVIEW; SEQUENTIAL PARALLEL DESIGN; TREATMENT RESPONSE;

EID: 64249151478     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2009.6.1.1     Document Type: Review

References (27)

1. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J; PhRMA Working Group. Adaptive designs in clinical drug development-an Executive Summary of PhRMA Working Group. J Biopharm Stat 2006;16:275-283; discussion 285-291, 293-298, 311-312.
2. Murphy SA, Collins LM, Rush AJ. Customizing treatment to the patient: adaptive treatment strategies. Drug Alcohol Depend 2007;88 Suppt 1 2:S1-S3.
3. Chang M, Chow SC, Pong A. Adaptive design in clinical research: issues, opportunities, and recommendations. J Biopharm Stat 2006;16: 299-309; discussion 311-312.
4. Wisniewski SR. Adaptive treatment strategies: what is their role in psychopharmacological clinical trials. 48th Annual NCDEU Meeting May 27-30, 2008
5. Lavori PW, Rush AJ, Wisniewski SR, Alpert J, Fava M, Kupfer DJ, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 2001;50:792-801.
6. Rush AJ, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry 2003;160:237.
7. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003;72:115-127.
8. Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials 2007;4:309-317.
9. Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006;5:133-146.
10. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
11. Khan A, Kolts RL, Rapaport MH, Krishnan KR, Brodhead AE, Browns WA. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med 2005;35:743-749.
12. Berman RM. A case study on a trial design for treatment resistant depression: applying old saws and new tools. 48th Annual NCDEU Meeting May 27-30, 2008.
13. Meta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W; BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007;9:413-425.
14. Thase ME, Maefadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609.
15. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-853.
16. Marcus, RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, ramdomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28:156-165.
17. Schatzberg AF, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol Psychiatry 2000;47:736-744.
18. Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1994;11:33-43.
19. Merlo-Pich E. Improving clinical trials in depression using signal detection theory and biomarkers. 48th Annual NCDEU Meeting May 27-30, 2008.
20. Merlo-Pich E, Gomeni R. Model-based approach and signal detection theory to evaluate the performance of recruitment centers in clinical trials with antidepressant drugs. Clin Pharmacol Ther 2008;84:378-394.
21. Sugarman J, McCrory DC, Powell D, Krasny A, Adams B, Ball E, et al. Empirical research on informed consent. An annotated bibliography. Hastings Cent Rep 1999;29:S1-S42.
22. Schwartz V, Appelbaum PS. Improving the quality of informed consent to research. IRB 2008;30:19-20.
23. Beauchamp TC, Childress JE. Principles of Biomedical Ethics. 4th ed. New York: Oxford University Press; 1994.
24. Lavori PW, Sugarman J, Hays MT, Feussner JR. Improving informed consent in clinical trials: a duty to experiment. Controlled Clin Trials 1999;20:187-193.
25. Dunn LB, Lindamer LA, Palmer BW, Golshan S, Schneiderman LJ, Jeste DV. Improving understanding of research consent in middle-aged and elderly patients with psychotic disorders, Am J Geriatr Psychiatry 2002;10:142-150.
26. Wirshing DA, Wirshing WC, Marder SR, Liberman RP, Mintz J. Informed consent: assessment of comprehension. Am J Psychiatry 1998; 155:1508-1511.
27. Fava M. Limitations of current approaches to study design in CNS clinical trials. 48th Annual NCDEU Meeting May 27-30, 2008.